Taro Pharmaceutical Industries Ltd. (TARO) News

Taro Pharmaceutical Industries Ltd. (TARO): $35.46

-0.09 (-0.25%)

POWR Rating

Component Grades













Filter TARO News Items

TARO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest TARO News From Around the Web

Below are the latest news stories about Taro Pharmaceutical Industries Ltd that investors may wish to consider to help them evaluate TARO as an investment opportunity.

Taro Completes Acquisition of Alchemee

HAWTHORNE, N.Y., February 28, 2022--Taro Completes Acquisition of Alchemee

Yahoo | February 28, 2022

Taro Pharmaceutical to acquire Alchemee from Galderma

Taro Pharmaceutical Industries (TARO) will acquire Alchemee from Galderma.The deal includes Alchemees business as well as its flagship acne care brand Proactiv.

Seeking Alpha | February 22, 2022

Taro to Acquire Alchemee From Galderma

ZUG, Switzerland & HAWTHORNE, N.Y., February 22, 2022--Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro") announced today they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from Galderma. The agreement between Galderma and Taro includes Alchemee’s business and assets around the world, including the Proactiv® brand.

Yahoo | February 22, 2022

Taro Pharmaceutical (TARO) Q3 Earnings and Revenues Miss Estimates

Taro (TARO) delivered earnings and revenue surprises of -23.08% and 2.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | January 28, 2022

Taro Provides Results for December 31, 2021


Yahoo | January 27, 2022

Taro Pharmaceutical Q3 2022 Earnings Preview

Taro Pharmaceutical (NYSE:TARO) is scheduled to announce Q3 earnings results on Thursday, January 27th, after market close.The consensus EPS Estimate is $0.91 (+37.9% Y/Y) and the…

Seeking Alpha | January 26, 2022

Is The Market Rewarding Taro Pharmaceutical Industries Ltd. (NYSE:TARO) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?

It is hard to get excited after looking at Taro Pharmaceutical Industries' (NYSE:TARO) recent performance, when its...

Yahoo | January 25, 2022

Taro to Announce Third Quarter Results on January 27, 2022

HAWTHORNE, N.Y., January 21, 2022--Taro to Announce Third Quarter Results on January 27, 2022

Yahoo | January 21, 2022

Taro Pharmaceutical (TARO) Earnings Expected to Grow: Should You Buy?

Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | January 19, 2022

H.C. Wainwright Maintains Their Buy Rating on Taro Pharmaceutical (TARO)

In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Buy rating on Taro Pharmaceutical (TARO – Research Report), with a price target of $75.00. The company's shares closed last Friday at $48.57, close to its 52-week low of $45.00. According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -24.8% and a 20.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. Currently, the analyst consensus on Taro Pharmaceutical is a Moderate Buy with an average price target of $75.00.

Christine Brown on TipRanks | January 18, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.4924 seconds.